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C patients receiving peginterferon plus
ribavirinCombination therapy with pegylated interferon (Peg-IFN)
and ribavirin can achieve a satisfactory sustained virologic
response rate for the treatment of patients with chronic
hepatitis C (CHC), and is still recommended in many
countries including Taiwan in the era of directly acting
antivirals (DAAs) [1e6]. This therapy is even more cost
effective in the Asia-Pacific region because of a favorable
IL28B genetic background However, patients receiving Peg-
IFN combination therapy may develop significant anemia,
which may lead to dose reduction and treatment discon-
tinuation, and therefore negatively influence the treatment
outcomes [7e9]. The presence of severe anemia may also
result in the development of cardiovascular complications.
A number of mechanisms have been proposed for the
occurrence of anemia, such as dose-dependent ribavirin-
induced hemolysis [10] and/or interferon-induced bone
marrow suppression [10,11]. Clarification of the underlying
mechanisms and identification of biomarkers for prediction
of significant anemia would be of clinical significance.
Reticulocyte count is a useful clinical parameter of red
blood cell production. After adjustment, reticulocyte pro-
duction index (RPI) is derived and has been shown to reflect
the bone marrow response to anemia [12]. Yan et al [13]
thus aimed to examine the value of RPI as a biomarker
for predicting clinically significant anemia in patients
receiving Peg-IFN combination therapy in a prospective
cohort of 69 patients with CHC. They found that clinically
significant anemia was observed in 30 patients (43.5%). On
multivariate analysis, older age > 60 years, low pretreat-
ment hemoglobin level, and low RPI at Week 4 of the
combination therapy were significantly associated with the
development of meaning anemia. Specifically, RPI < 0.9% at
Week 4 had an odds ratio of 5.50 for the development of
clinically significant anemia.
The merits of this manuscript include its novelty in the
adoption of RPI as a biomarker for predicting anemia devel-
opment. In addition, the prospective study design wouldhttp://dx.doi.org/10.1016/j.aidm.2016.01.001
2351-9797/Copyrightª 2016, The Gastroenterological Society of Taiwan
for the Study of the Liver. Published by Elsevier Taiwan LLC. This is
creativecommons.org/licenses/by-nc-nd/4.0/).avoid information and recall bias. The weaknesses of this
manuscript include small case number, heterogeneity in the
enrolment of both Genotype 1 and Genotype 2 patients with
different treatment duration, and notably a lack of genetic
information regarding inosine triphosphatase (ITPA) gene
polymorphism. There is growing evidence that variations in
the gene encoding inosine triphosphate pyrophosphohy-
drolase (ITPase), known as ITPA, are related to hemolytic
anemia, which is frequently observed among CHC patients
receiving ribavirin-containing therapy [14]. ITPA poly-
morphisms, particularly rs1127354 CC and rs7270101 AA ge-
notypes, increase the likelihood of developing hemolytic
anemia. Unfortunately, information on these gene poly-
morphisms was not available and not taken into consider-
ation. Moreover, other potential causes of anemia were not
investigated at the same time. For example, serum iron
profile was not examined at all. Both reduced production and
increased destruction of red blood cells are responsible for
thedevelopmentof anemia.The relativecontributionof each
pathogenetic process to the development of anemia has not
yet been clarified. Serial and comprehensive examinations of
all parameters relevant to the development of anemia
including RPI through the course of treatment would help
resolve this issue. Finally, ribavirin induced hemolysis has
beenproposedas a novelmechanismof actionagainst chronic
hepatitis C virus infection through anti-inflammatory/
antiviral actions within the liver [15]. In the future, whether
RPI could predict the treatment responses in addition to the
development of hemolytic anemia should be clarified.
Overall, clinical applications of the current study find-
ings can be expected. RPI is a routinely used laboratory test
and is available in all medical centers or offices. Develop-
ment of this predictive biomarker would help general
practitioners to easily identify clinically significant anemia
early during the course of Peg-IFN-based combination
therapy for patients with CHC, and allow prompt manage-
ment of anemia to avoid potential complications., The Digestive Endoscopy Society of Taiwan and Taiwan Association
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